LDL-C-lowering therapies reduce major vascular events in patients aged ≥75 y

Islam Y Elgendy; Mohamed B Elshazly

doi:10.7326/ACPJ202104200-038

LDL-C-lowering therapies reduce major vascular events in patients aged ≥75 y

Ann Intern Med. 2021 Apr;174(4):JC38. doi: 10.7326/ACPJ202104200-038. Epub 2021 Apr 6.

Authors

Islam Y Elgendy¹, Mohamed B Elshazly¹

Affiliation

¹ Weill Cornell Medicine-Qatar, Doha, Qatar (I.Y.E., M.B.E.).

PMID: 33819068
DOI: 10.7326/ACPJ202104200-038

Abstract

Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396:1637-43. 33186535.

Keywords: Anticholesteremic agents; Cholesterol, LDL, Ezetimibe; Risk reduction behavior.

Publication types

Comment

MeSH terms

Aged
Anticholesteremic Agents* / adverse effects
Cardiovascular Diseases* / prevention & control
Cholesterol, LDL
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Treatment Outcome

Substances

Anticholesteremic Agents
Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors